Provided by Tiger Trade Technology Pte. Ltd.

Century Therapeutics, Inc.

2.24
-0.1850-7.64%
Volume:876.62K
Turnover:2.00M
Market Cap:402.30M
PE:-20.19
High:2.52
Open:2.45
Low:2.20
Close:2.42
52wk High:3.04
52wk Low:0.3418
Shares:180.00M
Float Shares:112.00M
Volume Ratio:0.74
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1107
EPS(LYR):-0.1107
ROE:-5.98%
ROA:-3.26%
PB:2.53
PE(LYR):-20.19

Loading ...

Century Therapeutics Rocked by Dual Insider Moves at the Top

TIPRANKS
·
Mar 17

Century Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Century Therapeutics Reports 2025 Results and Pipeline Progress

TIPRANKS
·
Mar 12

Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate

Benzinga
·
Mar 12

Century Therapeutics 2025 net loss narrows beating estimates

Reuters
·
Mar 12

Century Therapeutics FY2025 net loss narrows 92% to USD 9.58 million on collaboration revenue of USD 109.16 million

Reuters
·
Mar 12

BRIEF-Century Therapeutics FY Net Income USD -9.58 Million

Reuters
·
Mar 12

Century Therapeutics FY Operating Expenses USD 126.433 Million

THOMSON REUTERS
·
Mar 12

Century Therapeutics Inc - Cnty-813 Ind Submission Expected in Q4 2026; Initial Clinical Data Anticipated in 2H 2027

THOMSON REUTERS
·
Mar 12

Press Release: Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Dow Jones
·
Mar 12

Century Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
Feb 27

Century Therapeutics to Participate in Upcoming Investor Conferences in March

GlobeNewswire
·
Feb 25

Century Therapeutics initiated with a Buy at TD Cowen

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Century Therapeutics files to sell 176.09M shares of common stock for holders

TIPRANKS
·
Feb 06

Century Therapeutics Files Prospectus to Offer, Resale From Time to Time by Selling Stockholders of up to 176.1 Mln Shares of Common Stock

THOMSON REUTERS
·
Feb 06

Century Therapeutics Inc held special shareholder meeting

Reuters
·
Jan 26

Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split

TIPRANKS
·
Jan 24

Century Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 20

Century Therapeutics price target raised to $4 from $2 at Piper Sandler

TIPRANKS
·
Jan 20